STOK · Stoke Therapeutics, Inc.

Dr. Kahn’s appointment strengthens Stoke’s governance and scientific oversight at a critical stage in the development of zorevunersen, its Phase 3 antisense oligonucleotide for Dravet syndrome. Her background in regulatory strategy and drug development—spanning leadership roles at Pfizer, GlaxoSmithKline, and X-VAX Technology—directly supports Stoke’s near-term priorities: advancing the ongoing Phase 3 trial, preparing for potential regulatory submissions, and executing its strategic collaboration with Biogen. As chair of the Research and Development Committee, she assumes responsibility for overseeing clinical strategy, regulatory interactions, and pipeline progression—functions central to de-risking the program and informing future valuation catalysts. The Board’s formal determination of her independence and execution of Stoke’s standard indemnity agreement underscore compliance rigor. While director appointments are routine governance events, this addition carries elevated relevance given Stoke’s late-stage clinical inflection point and the absence of approved disease-modifying therapies for Dravet syndrome—a context explicitly highlighted in Exhibit 99.1.